What is the etiology of irritable bowel syndrome and what are the latest updates in its treatment?

Irritable Bowel Syndrome: Etiology and Treatment Updates

Etiology

IBS is fundamentally a disorder of gut-brain interaction, not a purely functional disorder, with multiple organic mechanisms now identified including post-infectious changes, visceral hypersensitivity, gut microbiome dysbiosis, bile acid dysregulation, low-grade inflammation, and stress-axis dysfunction 1, 2.

The key pathophysiological mechanisms include:

• Gut-brain axis dysfunction: Bidirectional communication disruption between the central nervous system and enteric nervous system, with neurotransmitter imbalances (particularly serotonin) affecting motility and visceral pain 3
• Microbiome alterations: Reduced microbial diversity leading to intestinal barrier dysfunction and heightened inflammation susceptibility 3
• Post-infectious changes: Persistent alterations following gastrointestinal infections (PI-IBS) 2, 4
• Visceral hypersensitivity: Heightened pain perception from normal gut stimuli 1
• Psychological factors: Coexisting anxiety, depression, adverse life experiences, and chronic stress upregulating cortisol secretion and exacerbating symptoms 1, 3
• Bile acid dysregulation: Particularly relevant in IBS with diarrhea (IBS-D) 5, 2

---

Treatment Algorithm

First-Line Treatments

Start with dietary modifications and lifestyle interventions before pharmacotherapy 5:

Dietary Interventions (in order of recommendation strength):

1. Soluble fiber (ispaghula): Start at 3-4 g/day, titrate gradually to avoid bloating. Avoid insoluble fiber (wheat bran) as it worsens symptoms 5

2. Low FODMAP diet (second-line dietary therapy): Implement under trained dietitian supervision with systematic reintroduction according to tolerance 5. Shows significant reduction in abdominal pain severity and bloating 4

3. Probiotics: Consider 12-week trial, discontinue if no improvement. Bifidobacteria and Lactobacilli strains show the most efficacy for global symptoms and abdominal pain, though specific strain recommendations cannot be made 5, 6

4. Do NOT recommend: IgG antibody-based elimination diets or gluten-free diets 5

Symptom-Specific First-Line Pharmacotherapy:

• For diarrhea: Loperamide, titrating dose carefully to avoid constipation, bloating, and nausea 5
• For abdominal pain/spasm: Antispasmodics (expect dry mouth, visual disturbance, dizziness) 5
• For constipation: Laxatives (not detailed in provided guidelines but standard practice)

---

Second-Line Treatments

When first-line therapies fail, escalate to gut-brain neuromodulators or IBS subtype-specific agents 5, 7:

Gut-Brain Neuromodulators (for all IBS subtypes):

1. Tricyclic antidepressants (TCAs): This is the strongest second-line recommendation for global symptoms and abdominal pain 5, 7

   • Start amitriptyline 10 mg once daily
   • Titrate slowly to maximum 30-50 mg once daily
   • Provide careful explanation of rationale (neuromodulation, not depression treatment)
   • Can be initiated in primary or secondary care
   • AGA suggests using TCAs in IBS (conditional recommendation, low certainty) 7

2. SSRIs: Weaker evidence than TCAs for global symptoms 5

   • AGA suggests AGAINST using SSRIs in IBS (conditional recommendation, low certainty) 7
   • This represents a divergence: British guidelines suggest conditional use 5, while AGA recommends against 7

IBS-D Specific Second-Line Agents:

For IBS-D, 5-HT3 receptor antagonists are likely the most efficacious drug class 5:

1. Ondansetron: 4 mg once daily, titrate to maximum 8 mg three times daily (constipation is common side effect) 5

   • Alternative to alosetron/ramosetron where unavailable

2. Eluxadoline: Mixed opioid receptor drug 5, 7

   • AGA suggests using eluxadoline (conditional, moderate certainty) 7
   • Contraindications: Prior sphincter of Oddi problems, cholecystectomy, alcohol dependence, pancreatitis, severe liver impairment 5

3. Rifaximin: Non-absorbable antibiotic 5, 7

   • AGA suggests using rifaximin and retreatment for recurrent symptoms (conditional, moderate certainty) 7
   • Limited effect on abdominal pain 5

4. Alosetron: 5-HT3 antagonist 7

   • AGA suggests using alosetron (conditional, moderate certainty) 7
   • Unavailable in many countries 5

IBS-C Specific Second-Line Agents:

• Linaclotide: Guanylate cyclase-C agonist (mentioned but details cut off in evidence) 5

---

Emerging and Adjunctive Therapies

• Psychological therapies: Cognitive behavioral therapy and gut-directed hypnotherapy show evidence for efficacy 1
• Fecal microbiota transplantation (FMT): Promising emerging intervention addressing microbiome dysbiosis 3, 8
• Synbiotics: Show significant reduction in abdominal pain severity and gut-related anxiety, potentially more effective than prebiotics alone 6

---

Critical Diagnostic Considerations

Do NOT perform colonoscopy unless alarm symptoms present or specific risk factors for microscopic colitis exist (female sex, age ≥50, autoimmune disease, nocturnal/severe watery diarrhea, duration <12 months, weight loss, NSAID/PPI use) 5.

For IBS-D with atypical features (nocturnal diarrhea, prior cholecystectomy): Consider SeHCAT scanning or serum 7α-hydroxy-4-cholesten-3-one to exclude bile acid diarrhea 5.

Do NOT test for: Small intestinal bacterial overgrowth via breath testing, exocrine pancreatic insufficiency, or carbohydrate intolerance in typical IBS 5.

---

Common Pitfalls

• Avoid insoluble fiber (wheat bran) - it exacerbates symptoms despite being "fiber" 5
• Don't start soluble fiber at high doses - begin low (3-4 g/day) and build gradually 5
• Explain TCA rationale clearly - patients need to understand it's for neuromodulation, not depression treatment, to ensure adherence 5
• Screen for eluxadoline contraindications - particularly prior cholecystectomy and sphincter of Oddi problems 5
• Low FODMAP requires dietitian supervision - improper implementation or failure to reintroduce foods can lead to nutritional deficiencies 5